Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD64-anti-CD30 bispecific monoclonal antibody - Medarex

Drug Profile

Anti-CD64-anti-CD30 bispecific monoclonal antibody - Medarex

Alternative Names: H22xKi-4

Latest Information Update: 03 May 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medarex
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD30 antigen inhibitors; IgG receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hodgkin's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hodgkin's disease

Most Recent Events

  • 03 May 2007 Discontinued - Phase-I for Hodgkin's disease in USA (unspecified route)
  • 03 Apr 2003 Phase-I clinical trials in Hodgkin's disease in USA (unspecified route)
  • 03 Apr 2003 A study has been added to the adverse events, pharmacokinetics, pharmacodynamic and Cancer therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top